Speaker Profile

Ph.D., CEO and CSO, Bluestar Genomics

Biography
Dr Levy has been developing epigenomic based technology at Bluestar Genomics since 2017. These technologies have been focused on creating molecular tests for individual and multicancer detection in high-risk patients, as well as extended to test development for therapy response and minimal residual disease. Previously, Dr Levy employed tumor tissue-based models and single cell genomics for pre-clinical drug discovery as part of Quanticel Pharmaceuticals. He worked at Genomic Health leading research and development toward liquid based approaches for cancer diagnosis. His academic career included clinical genomics at Scripps Translational Science Institute and human genomics at J. Craig Venter Institute. Dr Levy’s genomics work commenced at Celera Genomics where he worked on genome assembly and annotation on the Drosophila, Mouse and the Human genomes.

Talk
Dynamic DNA De-methylation as Epigenomic Cancer Biomarkers
Dynamic DNA demethylation events can be measured in an unbiased accurate manner through click-chemistry based detection of 5-hydromethylcytosine (5hmC). Combining our epigenomic based proprietary 5hmC assay with machine learning enables the creation of blood based screening test for pancreatic cancer in patients with new onset type II diabetes.


 Session Abstract – PMWC 2022 Silicon Valley


The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.

Sessions:

  • Early Cancer Detection- Status quo, Technical and Clinical Challenges, and the Future (PANEL)
    Session Chair: Jimmy Lin, Freenome
    - Nicholas Dracopoli, delfi Diagnostics
    - Ash Alizadeh, Stanford
    - Amir Ali Talasaz, Guardant Health
    - Anne-Renee Hartman, Adela
  • How is Liquid Biopsy Changing the Testing Paradigm for Oncology Patients? (PANEL)
    Session Chair: Rebecca Brandes, Agilent
    - Kenna Anderes, Mirati
    - Kate Knobil, Agilent
  • The Emerging Role of ctDNA for Molecular Residual Disease (MRD) Assessment and Recurrence Monitoring
    - Alexey Aleshin, Natera
  • Liquid Biopsy for Screening, Diagnosis, Prognosis and Therapy Guidance
    Session Chair: Sam Salman, miR Scientific
    - Matt Franklin, Exact Sciences
  • The Advantages of Exosomes as a Liquid Biopsy Based Markers
    Session Chair: Johan Skog, Exosome Diagnostics
    - Jamil Azzi, Harvard
    - Dolores Di Vizio, Cedars-Sinai Medical Center
  • The Current Regulatory Landscape of Liquid Biopsy In Oncology
    Session Chair: Deepshikha Bhandari, Grail Bio
    - Seema Singh Bhan, Exact Sciences
    - Ryan Woodhouse, Foundation Medicine
  • Showcase
    - Samuel Levy, Bluestar Genomics
    - Richard Chen, Personalis